ClinicalTrials.gg
Drug

Ezabenlimab clinical trials

Also written BI 754091.

studies test it
16
open now
1
in phase 3
1
first study started
2016

How each study uses ezabenlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ezabenlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ezabenlimab
10

Development codes

BI 754091
10

Studies by the year they started

16 studies that test it; most in 2020 (3)

Studies that test ezabenlimab, by start year
YearStudies
20161
20172
20181
20192
20203
20211
20222
20232
20242

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
3
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 3

Boehringer Ingelheim (13) · National Health Research Institutes, Taiwan (1) · Johann Wolfgang Goethe University Hospital (1) · Institut Bergonié (1)

Often tested with

Tested in the same studies.

Anti-SIRPa Monoclonal Antibody BI 765063 (3) · Brigimadlin (3) · Obrixtamig (1) · VSV-GP-based Cancer Vaccine VSV-GP154 (1) · Therapeutic Cancer Vaccine ATP150 (1) · Therapeutic Cancer Vaccine ATP152 (1) · Therapeutic Cancer Vaccine ATP162 (1) · STING Agonist BI 1387446 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test ezabenlimab.

Studies

Open first, then newest update. How each study uses ezabenlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Given beside what is tested · 16 — ezabenlimab is usual care or a partner of the new treatment

Codes

What other systems call ezabenlimab · ClinicalTrials.gg INT015128

  • UNII (FDA) 5V1UI86573EZABENLIMABOne source FDA
  • NCI Thesaurus C132252EzabenlimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.